Eurofins offers Melamine testing
Brussels/ Nantes, April 24, 2007
Following the death of a number of dogs and cats in the United States, the American Food and Drug Administration (FDA) highlighted the presence of melamine in pet food and its ingredients such as wheat gluten, rice protein concentrate and corn gluten. Several products have by now been recalled from the market. Eurofins has reacted rapidly to our customers requests to analyse for melamine in a variety of products and offers the test in several of our laboratories both in Europe and in the USA. The method applied is the method recommended by FDA, derivatisation followed by GC-MS and has been validated through internal ring tests to ensure our clients receive data of the highest quality.
Eurofins offers a testing portfolio containing over 15.000 tests. Based on this very broad expertise, Eurofins is able to rapidly support its customers confronted with new urgent testing needs.
For further information please contact your Eurofins laboratory or contact directly:
|
Eurofins | Central Analytical Metairie (USA) E-mail: info@centralanalytical.com |
Eurofins | Wietz-Eggert-Jörissen Hamburg (Germany) E-mail: service@eurofins.de |
Notes for the editor:
Eurofins - a global leader in bio-analysis
Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.
With over 5,000 staff in more than 70 laboratories across 24 countries, Eurofins offers a portfolio of over 15,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to providing its customers with high quality services, accurate results in time and expert advice by our highly qualified staff.
The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach. Through R&D, in-licensing and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the Euronext exchange in Paris (ISIN FR0000038259) and the Frankfurt (WKN 910251) Stock Exchange (Reuters EUFI.LN, Bloomberg ERSC FP, ESF, EUFI.DE).
Important disclaimer:
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.